Takeda (NYSE: TAK) officer sells 47,586 ADS in tax-related transaction

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD executive Lauren Rusckowski Duprey, Chief Transformation Officer, reported selling 47,586 American Depositary Shares on 2026-08-10. The sale was described as a mandatory sale to cover taxes associated with vesting of equity awards. The reported $17.10 figure is a weighted average price for the transaction. After this sale, Duprey directly held 226,057 American Depositary Shares.

Insider Trade Summary

Net Seller: 47,586 shares

Net Sell 1 txn

Insider Duprey Lauren Rusckowski

Role Chief Transformation Officer

Sold 47,586 shs ($814K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2	47,586	$17.10	$814K

Holdings After Transaction: American Depositary Shares — 226,057 shares (Direct)

Footnotes (2)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 47,586 American Depositary Shares Weighted average sale price: $17.10 per American Depositary Share Shares held after transaction: 226,057 American Depositary Shares +1 more

4 metrics

Shares sold 47,586 American Depositary Shares Non-derivative sale on 2026-08-10 by Chief Transformation Officer

Weighted average sale price $17.10 per American Depositary Share Price reported for the 2026-08-10 sale transaction

Shares held after transaction 226,057 American Depositary Shares Direct ownership following the reported sale

Net shares sold 47,586 shares Net-sell direction across reported transactions in this Form 4

Key Terms

American Depositary Shares, weighted average price, equity awards

3 terms

American Depositary Shares financial

"The reporting person traded <b>American Depositary Shares</b> of Takeda Pharmaceutical."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"The price reported is described as a <b>weighted average price</b> per share."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

equity awards financial

"The sale covered taxes associated with the vesting of <b>equity awards</b>."

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

FAQ

What insider transaction did TAK (Takeda Pharmaceutical) report for Lauren Rusckowski Duprey?

Takeda reported that Lauren Rusckowski Duprey, Chief Transformation Officer, sold 47,586 American Depositary Shares on 2026-08-10. The transaction was a mandatory sale to cover taxes tied to vesting equity awards.

How many TAK American Depositary Shares does Lauren Rusckowski Duprey hold after the reported sale?

Following the transaction, Lauren Rusckowski Duprey directly holds 226,057 American Depositary Shares of Takeda Pharmaceutical. This post-transaction balance was reported in the Form 4’s ownership column for non-derivative securities.

What price was received in the TAK insider sale by Lauren Rusckowski Duprey?

The reported sale used a weighted average price of $17.10 per American Depositary Share. A footnote states the insider can provide details on the number of shares sold at each separate price within the disclosed ranges.

Was the August 10, 2026 TAK insider sale related to a trading plan or tax obligations?

The Form 4 footnote states the transaction was a mandatory sale to cover taxes from vesting equity awards. It does not describe the trade as being executed under a Rule 10b5-1 trading plan in the document-level checkbox.

What role does the reporting person in the TAK Form 4 hold at Takeda Pharmaceutical?

The reporting person, Lauren Rusckowski Duprey, is identified as Chief Transformation Officer of Takeda Pharmaceutical. She is not listed as a director or 10% owner, but as an officer of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 09:51 PM Accepted by SEC EDGAR 08/12/2026 - 09:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duprey Lauren Rusckowski

(Last) (First) (Middle)

45-55 HAYDEN AVE.

(Street)

LEXINGTON MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Transformation Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		47,586	D	$17.1(2)	226,057	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Lauren R. Duprey	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)